TAVI in patients at low surgical risk is a cost-efective alternative to SAVR in the French healthcare system. Longer follow-up data will help increase the accuracy of lifetime survival projections
Cost-effectiveness of transcatheter aortic valve implantation in patients at low surgical risk in France: a model-based analysis of the Evolut LR trial